Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment
نویسندگان
چکیده
منابع مشابه
Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment
OBJECTIVE We aimed to investigate the ability of natalizumab (NTZ)-treated patients to assume treatment-associated risks and the factors involved in such risk acceptance. METHODS From a total of 185 patients, 114 patients on NTZ as of July 2011 carried out a comprehensive survey. We obtained disease severity perception scores, personality traits' scores, and risk-acceptance scores (RAS) so th...
متن کامل[Natalizumab treatment in multiple sclerosis].
Multiple sclerosis is a neurodegenerative and inflammatory immune disorder in the central nervous system (CNS). Most patients show relapse-remitting clinical course. Some disease modifying medications for preventing the relapses including natalizumab (NTZ) are approved in Japan. Natalizumab (NTZ), a monoclonal antibody against α4 integrin present on the surface of lymphocytes, inhibits the bind...
متن کاملNatalizumab treatment for multiple sclerosis.
Correspondence: Maria Lucia Brito Ferreira; Rua Doutor José Maria, 841; 52040-000 Recife PE, Brasil; E-mail: [email protected] Conflict of interest: There is no conflict of interest to declare. Received 23 September 2014 Accepted 01 October 2014 The last five years had as benchmark the development of new drugs for treatment of multiple sclerosis. Its treatment has become complex because othe...
متن کاملNatalizumab in the treatment of multiple sclerosis
Natalizumab is a monoclonal antibody, representing a new class of medication for treating relapsing multiple sclerosis (MS). Conventional treatments include interferons, glatiramer acetate and chemotherapies such as mitoxantrone and cyclophosphamide. These therapies offer only modest clinical benefits and are commonly not tolerated due to side effects. Natalizumab has been proven in large-scale...
متن کاملNatalizumab in pediatric multiple sclerosis patients.
Pediatric multiple sclerosis (MS) comprises 2-5% of all cases of MS. Although first-line disease-modifying therapy (DMT) including interferons and glatiramer acetate appear to be well tolerated in this population, recent work has suggested that a growing number of children suffer from disease which is resistant to treatment with these therapies. Natalizumab is a therapy which, although associat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: PLoS ONE
سال: 2013
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0082796